Chardan Capital Initiates Coverage on Tvardi Therapeutics (NASDAQ:TVRD)

Research analysts at Chardan Capital started coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a report issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating on the stock.

TVRD has been the topic of a number of other research reports. BTIG Research cut their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. Finally, Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $9.40.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD traded down $0.05 during mid-day trading on Tuesday, reaching $0.97. 55,405 shares of the company’s stock were exchanged, compared to its average volume of 788,715. The firm has a market capitalization of $12.97 million, a price-to-earnings ratio of -0.35 and a beta of 0.38. The business’s fifty day moving average price is $1.50 and its 200-day moving average price is $2.42. Tvardi Therapeutics has a twelve month low of $0.93 and a twelve month high of $5.69.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Tvardi Therapeutics in the second quarter valued at $181,000. Susquehanna International Group LLP acquired a new position in Tvardi Therapeutics in the second quarter valued at $63,000. Finally, GSA Capital Partners LLP acquired a new position in Tvardi Therapeutics in the second quarter valued at $34,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.